CELL LINES
Contributor Information
- Name Ghanem Elias, Ahmad Najem
- Institute UniversitĂŠ libre de Bruxelles
- Primary citation Eves et al. 2003. Br J Cancer 89. PMID: 14612916
Tool Details
- Tool name: MM001-HBL-R (TKI)cell line
- Tool type: Cell Line
- Parental cell line: Ham's F10 melanoma culture medium (HMCM)
- Organism: Human
- Tissue: Lymphatic
- Gender: Female
- Cancer type: Melanoma
- Disease: Cancer
- Growth properties: Adherent
- Model: C-KIT: D820Y
- Model description: This cell line displays a Proliferative/ Melanocyte-like phenotype
- CRISPR: No
- Application: High-throughput screening/Drug testing - 3D cell cultures-This cell line is a suitable transfection host-MM001/HBL-R (Dasatinib, Sunitinib) is tumorigenic: Cells produce xenograft tumors when injected into immunocompromised mice.
- Description: Cell Pigmentation: Eumelanotic cell line. Drug response: This cell line displays an acquired resistance to TKI (Dasatinib, Sunitinib).
- Research area: Cancer
- For Research Use Only
Target Details
Application Details
- Application: High-throughput screening/Drug testing - 3D cell cultures-This cell line is a suitable transfection host-MM001/HBL-R (Dasatinib, Sunitinib) is tumorigenic: Cells produce xenograft tumors when injected into immunocompromised mice.
Handling
- Format: Frozen
- Growth medium: Hamâs F10 supplemented with 10% of fetal calf serum (FCS), with L-glutamine (1mM), penicillin (100 IU/ml), and streptomycin (100 Âľg/ml). Renewal 2 to 3 times per week
- Temperature: 37°C
- Atmosphere: 5% CO2
- Storage conditions: Liquid Nitrogen
- Shipping conditions: Dry Ice
- Initial handling information: The frozen culture should be stored in liquid nitrogen upon arrival or thaw the vial and initiate the culture as soon as possible upon receipt
- Subculture routine: Split sub-confluent cultures (70-80%) 1:3 to 1:8
- Cultured in antibiotics?: Yes
- Biosafety level: BSL-2
Documentation
- Available on request
Related Tools
References
- • Sabbah et al. 2021. Mol Cancer Res. 19(7):1221-1233. PMID: 33741716
- • Krayem et al. 2014. Eur J Cancer. 50(7):1310-20. PMID: 24559688
- • Krayem et al. 2018. Oncotarget. 9(61):31888-31903. PMID: 30159130
- • Soumoy et al. 2020. Cancers (Basel). 12(5):1323. PMID: 32455924
- • Porcelli et al. 2015. J Transl Med. 13:26. PMID: 25623468
- • Wouterset al. 2020. Nat Cell Biol. 22(8):986-998. PMID: 32753671
- • Verfaillie et al. 2015. Nat Commun 6, 6683. PMID: 25865119
- • Aftimos et al. 2013. Int J Oncol. 43(3):919-26. PMID: 23835698
- • Zannat et al. 2013. J Biol Regul Homeost Agents. 27(1):131-41. PMID: 23489693
- • Mauduit et al. 2021. eLife 10:e71735. PMID: 34874265
- • Huang et al. 2021. J Clin Invest. 131(8):e140752. PMID: 33690225
.svg)
.svg)
